Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EX-527 for endometrial receptivity in IVF failure
NCT04184323Phase 2Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in infertility and endometriosis comparing EX-527 with Placebo (2 arms). Primary endpoint: Live Birth Rate. Planned start Jan 2022; status: withdrawn.
02
Drugs
Selisistat
03
Conditions
infertilityendometriosis
Beyond the preview
Go deeper on NCT04184323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04184323.